BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) characterized in the peer-reviewed literature as a stabilized fragment related to a protein identified in human gastric juice. It has been studied extensively in rodent and cell-culture models as a probe of tissue repair, angiogenesis, and cytoprotection across multiple organ systems. A specific high-affinity receptor has not been established, and much of the reported mechanistic model is inferred from downstream signaling readouts such as the nitric-oxide system. This monograph summarizes published research findings and is intended strictly for laboratory and research use.

Background & Discovery

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide composed of 15 amino acids (sequence GEPPPGKPADDAGLV). Published literature characterizes it as a partial, stabilized fragment derived from a larger protein—Body Protection Compound (BPC)—that was originally identified in human gastric juice. The peptide was first characterized by Predrag Sikiric and colleagues at the University of Zagreb, Croatia, whose research group has produced the majority of the primary experimental literature on the molecule over several decades. Because the fragment is reported to remain stable in human gastric juice for extended periods, it became a focus of study as a potential orally and parenterally accessible cytoprotective agent in animal models.

The scientific interest in BPC-157 grew out of the broader concept of gastric cytoprotection introduced by Andre Robert, in which agents preserve mucosal integrity independent of acid suppression. Researchers positioned BPC-157 as a candidate novel cytoprotective mediator that appeared, in rodent studies, to protect and support healing across a wide range of tissues beyond the stomach—including the gastrointestinal tract, tendon, ligament, muscle, bone, nerve, cornea, and blood vessels. This unusually broad organ profile in preclinical models is a recurring theme in the peer-reviewed literature and is the primary reason the compound has been studied so extensively in experimental settings.

In terms of research category, BPC-157 is classified as an investigational research peptide. It has not been approved by the FDA or comparable regulatory agencies for human therapeutic use, and human clinical data remain limited (early-phase safety work and small trials in inflammatory bowel disease have been described in the literature). It is included on the World Anti-Doping Agency (WADA) Prohibited List. Within a laboratory context, it is studied as a tool compound for probing angiogenesis, nitric-oxide signaling, and tissue-repair biology. This monograph summarizes what peer-reviewed research reports and is intended strictly for laboratory and research use.

Chemical Identity

Structure & Physicochemical Properties

BPC-157 is a linear pentadecapeptide with the molecular formula C62H98N16O22 and an average molecular weight of approximately 1419.5 g/mol. A distinctive structural feature is its high proline content—the sequence contains four proline residues, including a Pro-Pro-Pro triplet—which is frequently cited in the literature as conferring conformational rigidity and contributing to the reported resistance to enzymatic and acid-mediated degradation. Reference databases characterize the peptide as unusually stable in aqueous acidic conditions such as human gastric juice, a property that distinguishes it from many other bioactive peptides that are rapidly hydrolyzed in the gastrointestinal environment.

In its research-supply form, BPC-157 is typically a lyophilized white-to-off-white powder, most commonly isolated as an acetate or trifluoroacetate salt following reversed-phase HPLC purification. It is generally described as freely soluble in water and in bacteriostatic or sterile aqueous buffers, and it carries a net acidic character owing to its glutamate and two aspartate residues balanced against a single lysine. The lyophilized solid is regarded as relatively stable when stored cold and desiccated, whereas reconstituted aqueous solutions are treated as less stable and are typically stored refrigerated and protected from repeated freeze-thaw cycling for research handling.

Mechanism of Action — as described in the literature

The most consistently reported mechanistic theme for BPC-157 in the peer-reviewed literature is its interaction with the nitric oxide (NO) system. Reviews by Sikiric and colleagues describe the peptide as participating in the endothelial NO pathway, influencing endothelial nitric oxide synthase (eNOS) activity and NO release, and modulating both NO-agonist (L-arginine) and NO-blockade (L-NAME) effects in experimental preparations. This NO-system relationship is proposed as an integrating framework that links the peptide’s vascular, cytoprotective, and wound-healing observations reported across many rodent models.

At the vascular signaling level, controlled in-vitro and ex-vivo work has provided more granular detail. In isolated rat aortic ring preparations, researchers reported that BPC-157 produced concentration- and NO-dependent modulation of vasomotor tone and activated a Src-Caveolin-1-eNOS signaling cascade, with pharmacological inhibition of Src kinase abolishing the downstream response. In parallel, angiogenesis-focused studies describe upregulation and enhanced signaling of vascular endothelial growth factor receptor 2 (VEGFR2) and its downstream Akt-eNOS axis, associating the peptide with endothelial cell proliferation, migration, and new vessel formation.

A second major mechanistic pillar concerns direct effects on reparative cell populations. In cultured tendon fibroblasts derived from rat Achilles tendon, BPC-157 accelerated the outgrowth of cells from tendon explants and promoted dose-dependent cell migration accompanied by increased F-actin formation and phosphorylation of focal adhesion kinase (FAK) and paxillin—components of the FAK-paxillin cytoskeletal/adhesion signaling pathway. In these experiments cell survival under oxidative (H2O2) stress was increased even though baseline proliferation was not directly stimulated, suggesting a pro-survival and pro-migratory rather than simply mitogenic action.

Beyond the periphery, literature on the brain-gut and gut-brain axes proposes that BPC-157 exerts coordinated central and peripheral effects. Reviews describe interactions with multiple neurotransmitter systems (including dopaminergic, serotonergic, adrenergic, and GABAergic signaling) and activation of alternative vascular ‘bypassing’ pathways—such as rapid recruitment of collateral circulation—that authors argue underlie observations of neuroprotection and functional recovery in various rodent lesion and vascular-occlusion models. This ‘one peptide, many tissues’ pattern is framed in the literature as a unified cytoprotective/adaptive response rather than a single receptor-specific action.

It is important to note the mechanistic caveats emphasized in the primary literature: a specific high-affinity BPC-157 receptor has not been definitively identified, and much of the mechanistic model is inferred from downstream pathway readouts (NO, VEGFR2, FAK/paxillin, growth-factor and gene-expression changes) rather than from a single defined molecular target. Authors of the reviews themselves acknowledge that translating these mechanistic observations from animal and cell systems into validated human pharmacology requires further investigation.

Key Published Findings

• Tendon-to-bone healing. In a rat model of Achilles tendon detachment from bone, researchers reported that BPC-157 promoted tendon-to-bone healing across functional, biomechanical, and histological measures and counteracted the healing impairment caused by corticosteroid administration, whereas the detached unit did not heal spontaneously in controls.[1]
• Ligament healing. In rats with surgically transected medial collateral ligaments followed for up to 90 days, BPC-157 delivered by intraperitoneal, oral (in drinking water), or topical routes produced consistent functional, biomechanical, macroscopic, and histological improvements in ligament healing compared with controls.[2]
• Cellular mechanism (tendon fibroblasts). In cultured rat Achilles tendon fibroblasts, BPC-157 accelerated outgrowth from tendon explants and dose-dependently increased cell migration, F-actin formation, and phosphorylation of FAK and paxillin, and improved cell survival under H2O2 oxidative stress without directly increasing baseline proliferation.[3]
• Vascular signaling / eNOS. In isolated rat aorta preparations, BPC-157 modulated vasomotor tone in a concentration- and nitric-oxide-dependent manner via activation of the Src-Caveolin-1-endothelial NO synthase (eNOS) pathway, with Src kinase inhibition abolishing the response.[4]
• Preclinical safety/toxicology. A formal preclinical safety evaluation reported that BPC-157 was well tolerated across mice, rats, rabbits, and dogs, with no serious toxicity and no genetic or embryo-fetal toxicity observed; a reversible decrease in creatinine at a higher dose in dogs was the main notable finding and resolved after withdrawal.[5]
• Myotendinous junction injury. In a rat model of transected myotendinous junction, BPC-157 therapy accelerated functional and structural recovery and counteracted muscle atrophy, with reported defect resolution over a 42-day period relative to poorly healing untreated controls.[6]

Research Applications

• Investigated in rodent models of tendon, ligament, and myotendinous-junction injury as a probe of connective-tissue repair.
• Studied in experimental gastrointestinal models (gastric mucosal lesions, intestinal anastomosis, inflammatory bowel disease models) for cytoprotection and mucosal integrity.
• Examined in in-vitro and in-vivo angiogenesis assays probing VEGFR2, Akt/eNOS, and endothelial cell migration and vessel formation.
• Used as a tool compound to interrogate the nitric-oxide (eNOS) signaling system, including L-arginine and L-NAME modulation studies.
• Investigated in rodent central nervous system and brain-gut/gut-brain axis models, including vascular-occlusion, nerve, and spinal cord lesion paradigms.
• Explored in preclinical wound-healing research across skin, cornea, muscle, bone, and blood-vessel injury models.
• Applied in preclinical safety and toxicology characterization across multiple species (mice, rats, rabbits, dogs).
• Studied in models examining counteraction of corticosteroid- and NSAID-associated tissue and mucosal injury.

Related & Comparator Compounds

Within the research literature, BPC-157 is most often discussed as a distinct member of the ‘cytoprotective peptide’ category rather than as a member of a defined receptor-ligand family, because a specific high-affinity receptor has not been established. It is sometimes compared with growth factors used in wound-healing research (such as VEGF, EGF, or bFGF); reviews note that BPC-157 is reported to act as a single agent without an added carrier, which authors contrast with growth factors that often require delivery systems and can show narrower stability. It is also frequently distinguished from thymosin beta-4 (TB-500), another peptide widely studied in tissue-repair and angiogenesis contexts, on the basis of a different sequence, structure, and mechanistic emphasis (actin sequestration for thymosin beta-4 versus NO-system and FAK/paxillin/VEGFR2 signaling reported for BPC-157). Historically, BPC-157 is a fragment-derived, stabilized construct related to the parent human gastric protein BPC, and its various development-code aliases (PL-10, PLD-116, PL 14736) reflect earlier pharmaceutical characterization of the same pentadecapeptide.

Handling, Reconstitution & Storage

As commonly described for research peptides, BPC-157 is typically supplied as a lyophilized powder that is stored frozen and desiccated (commonly at or below -20 C for long-term storage) and protected from light and moisture until use. In research settings the lyophilized solid is reconstituted with sterile or bacteriostatic water (or an appropriate aqueous buffer) to prepare stock solutions, after which working solutions are generally kept refrigerated (around 2-8 C) for short-term use and aliquoted to minimize repeated freeze-thaw cycles that can degrade peptide integrity. Because it is a peptide, exposure to elevated temperature, extreme pH, and prolonged solution storage are treated as stability risks. All handling described here refers strictly to in-vitro/laboratory research procedures; this section does not describe or imply any human administration, dose, or route.

Analytical & Quality Considerations

For research-grade material, identity and purity are typically established by reversed-phase high-performance liquid chromatography (RP-HPLC) to quantify chromatographic purity (commonly reported at 95% or higher) and by mass spectrometry (ESI-MS or MALDI-TOF) to confirm the molecular weight near 1419.5 Da and thereby the intended sequence. Amino acid analysis and, where available, sequencing further corroborate the GEPPPGKPADDAGLV composition, while residual analyses (water/moisture by Karl Fischer, residual solvents such as TFA or acetic acid, and counter-ion content) characterize the salt form and net peptide content. Because peptides sold for research are not manufactured under pharmaceutical GMP oversight and label claims can vary between suppliers, an independent third-party certificate of analysis (COA)—confirming HPLC purity, MS-verified identity, and net peptide content on the specific lot—is important for experimental reproducibility, allowing researchers to distinguish the target pentadecapeptide from truncated sequences, deletion/insertion impurities, or oxidation and deamidation products.

Frequently Asked Research Questions

Q. What is BPC-157?
A. BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV) characterized in the literature as a stabilized partial fragment related to a protein found in human gastric juice. It is used as a research compound and is studied primarily in animal and cell models of tissue repair, angiogenesis, and cytoprotection.

Q. Is BPC-157 approved for human use?
A. No. Published sources indicate BPC-157 has not been approved by the FDA or comparable regulatory agencies for human therapeutic use, and it appears on the World Anti-Doping Agency (WADA) Prohibited List. Human data are limited to early-phase safety work and small trials described in the scientific literature. It is offered strictly for laboratory and research use.

Q. What mechanisms are reported for BPC-157 in the literature?
A. Peer-reviewed studies most consistently describe interaction with the nitric-oxide system (eNOS, including Src-Caveolin-1-eNOS and VEGFR2-Akt-eNOS signaling), promotion of angiogenesis, and effects on reparative cells such as fibroblasts via the FAK-paxillin pathway. A single specific high-affinity receptor has not been definitively identified.

Q. What does preclinical research report about its safety profile?
A. A formal preclinical safety evaluation reported that BPC-157 was well tolerated across mice, rats, rabbits, and dogs, with no serious toxicity and no genetic or embryo-fetal toxicity observed in those studies. These findings pertain to animal research models and do not constitute human safety conclusions.

Q. How is BPC-157 typically characterized analytically?
A. Research material is generally analyzed by RP-HPLC for purity (often 95%+) and by mass spectrometry to confirm the molecular weight near 1419.5 Da. A lot-specific third-party certificate of analysis is important for confirming identity, purity, and net peptide content.

Q. How is it distinguished from thymosin beta-4 (TB-500)?
A. Both are peptides studied in tissue-repair and angiogenesis research, but they differ in sequence, structure, and reported mechanism. The literature emphasizes actin sequestration for thymosin beta-4, whereas BPC-157 studies emphasize nitric-oxide/eNOS signaling and FAK/paxillin/VEGFR2 pathways.

Peer-Reviewed References

1. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006. PubMed →
2. Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010. PubMed →
3. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology (1985). 2011. PubMed →
4. Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. 2020. PubMed →
5. Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, Zhang W, Wang S, Zhang K, He L, Zhang W, Zhang C, Hao Q, Zhang Y, Li M, Li W. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020. PubMed →
6. Japjec M, Horvat Pavlov K, Petrovic A, Staresinic M, Sebecic B, Buljan M, Seiwerth S, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines. 2021. PubMed →
7. Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, Boban Blagaic A, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021. PubMed →
8. Sikiric P, Gojkovic S, Krezic I, Smoday IM, Kalogjera L, Zizek H, Boban Blagaic A, Seiwerth S. Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function. Pharmaceuticals (Basel). 2023. PubMed →
9. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Stancic Rokotov D, Brcic L, Sebecic B. Stable gastric pentadecapeptide BPC 157-NO-system relation. Current Pharmaceutical Design. 2014. PubMed →
10. Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, Anic T. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006. PubMed →

For laboratory and research use only. Not for human or veterinary use, diagnosis, or treatment. This overview summarizes published scientific literature for informational and educational purposes and is not medical advice; no claims are made regarding safety or efficacy in humans.

← Back to the Research Library · View BPC-157 → · COA & Testing